Background Mucopolysaccharidoses (MPS) are a group of inborn errors of metabolism that are progressive and usually result in irreversible skeletal, visceral, and/or brain damage, highlighting a need for early diagnosis. Methods This pilot study analyzed 2862 dried blood spots (DBS) from newborns and 14 DBS from newborn patients with MPS (MPS I, n = 7; MPS II, n = 2; MPS III, n = 5). Disaccharides were produced from polymer GAGs by digestion with chondroitinase B, heparitinase, and keratanase II. Heparan sulfate (0S, NS), dermatan sulfate (DS) and monoand di-sulfated KS were measured by liquid chromatography tandem mass spectrometry (LC-MS/MS). Median absolute deviation (MAD) was used to determine cutoffs to distinguish patients from controls. Cutoffs were defined as median + 7× MAD from general newborns. Results The cutoffs were as follows: HS-0S > 90 ng/mL; HS-NS > 23 ng/mL, DS > 88 ng/mL; mono-sulfated KS > 445 ng/mL; di-sulfated KS > 89 ng/mL and ratio di-KS in total KS > 32 %. All MPS I and II samples were above the cutoffs for HS-0S, HS-NS, and DS, and all MPS III samples were above cutoffs for HS-0S and HS-NS. The rate of false positives for MPS I and II was 0.03 % based on a combination of HS-0S, HS-NS, and DS, and for MPS III was 0.9 % based upon a combination of HS-0S and HS-NS.
Introduction
Mucopolysaccharidoses (MPS) are inherited progressive and heterogeneous disorders caused by a deficiency of specific lysosomal enzymes responsible for the degradation of glycosaminoglycans (GAGs): chondroitin sulfate (CS), dermatan sulfate (DS), heparan sulfate (HS), keratan sulfate (KS), and hyaluronan. The MPS are classified according to the deficient enzyme as well as the undegraded GAGs and comprise 11 distinct subtypes, with an estimated combined incidence of 1 in 25,000 live births (Neufeld and Muenzer 2001) .
Accumulation of undegraded GAGs leads to progressive tissue damage in multiple organs causing disease-specific manifestations (e.g., coarse facial features, skeletal dysplasia, hepatosplenomegaly, corneal clouding, joint rigidity or laxity, cardiac and respiratory complications, and neurological impairment).
Although clinical manifestations usually do not appear at birth, accumulation of GAGs can be detected in the human fetus (MPS I, II, III, IVA) and placenta (MPS II, VI) (Beck et al 1992; Martin and Ceuterick 1983; Baldo et al 2011) indicating that the disease process starts and can be detected prior to appearance of clinical signs and symptoms. Several MPS-subtypes have specific enzyme replacement therapy available, and there are many indications that MPS patients treated at an early age do better than those treated later in life (Auclair et al 2003; McGill et al 2010; Gabrielli et al 2010; Schulze-Frenking et al 2011; Baldo et al 2013; Poe et al 2014; Muenzer 2014; Tomatsu et al 2016) . Newborn screening programs for MPSs using dried blood spots (DBS) were proposed in 2001 and high-throughput technologies such as tandem mass spectrometry (MS/MS) are now under investigation (Meikle et al 2006; Gelb et al 2006 Gelb et al , 2015 Wolfe et al 2011; de Ruijter et al 2012; Spacil et al 2013; Scott et al 2013; Lin et al 2013; Tomatsu et al 2013 Tomatsu et al , 2014 Shimada et al 2014a; Liao et al 2014; Gucciardi et al 2014; Ruijter et al 2014; Hopkins et al 2015) . Methods currently under development include assays for activity of deficient enzymes (Gelb et al 2015; Hopkins et al 2015) , measurement of accumulated GAGs (Oguma et al 2007; Tomatsu et al 2013; Lawrence et al 2012 Lawrence et al , 2014 .
In the present study, we analyzed 2862 de-identified DBS from unselected newborns and 14 DBS from newborns known to have MPS I, II, or III.
Material and methods

Materials
Chondroitinase B, heparitinase, keratanase II, chondrosine (internal standard-IS), and the unsaturated disaccharides: hep-
, and di-sulfated KS [Gal(6S) Galβ1-4GlcNAc(6S) were all provided by Seikagaku Co. (Tokyo, Japan). Stock solutions of HS-0S (100 μg/mL), HS-NS (100 μg/mL), Di-4S (250 μg/mL), mono-and di-sulfated KS (1000 μg/mL), and IS (5 μg/mL) were prepared in ddH 2 0 (Millipore Milli-Q Reference A+ System). Standard curves were prepared using dilutions of these stocks as follows: HS-0S, HS-NS, Di-4S, and monoand di-sulfated KS (78.13, 156.25, 312.50, 625, 1250 KS (78.13, 156.25, 312.50, 625, , 2500 , and 10,000 ng/mL). Standards were digested with chondroitinase B, heparitinase, and keratanase II. Acetonitrile optima® (A996-4), ammonium hydroxide ammoniaque optima® (A470-500), ammonium acetate optima ® LC/MS (A114-50), bovine serum albumin (BP1600-100), Corning Costar® Assay plate 96 well ref 3797 (07-200-105) , Thermo Scientific Hypercarb™ Porous Graphitic Carbon LC Columns (35005-052130), Thermo Scientific™ Uniguard™ Direct-connection guard cartridge holder (85200), Hypercarb 5 μm 10 × 2.1 mm drop-in guards (35005-012101), Thermal adhesive sealing film (08-408-240), and Tris Base (BP152-500) were purchased from Thermo Fisher Scientific (Ottawa, Ontario). Acroprep™ advance 96 filter plates 10 K Omega (PN 8034) were purchased from Pall Co (Ann Arbor, MI).
Samples
DBS samples of 2862 newborns were collected during routine newborn screening by Shimane University, Osaka City University, and Nagasaki University after informed consent was obtained. The samples were collected between 3 and 7 days after birth. Fourteen deidentified newborn DBS samples with MPS (MPS I: 7; MPS II: 2; MPS IIIA:3, MPS IIIB: 1, MPS IIIC: 1) were provided by the University of Amsterdam (The Netherlands) and St. Mary's Hospital (UK). All samples were shipped to Nemours/AIDHC and stored at −20°C until the GAG assay was conducted. This study was approved by IRBs at local institutes and Nemours/AIDHC.
Sample preparation
Two Disks (3.3 mm) were cut from DBS samples using a DBS puncher (PerkinElmer®; Waltham, MA) and placed into a 96 well omega 10 K filter plate with 100 μL of 0.1 % BSA on a 96 well receiver plate. Samples were incubated for 15 min and then centrifuged for 15 min at 2500 g. The filter plate was transferred to a new receiver plate and a cocktail mixture of: 90 μL of 50 mM Tris HCL (pH 7.0), 10 μL of 5 μg/mL IS, 10 μL of 0.5 mU chondroitinase B (in 1 % BSA), 1 mU heparitinase (in 1 % BSA), 10 μL of 1 mU keratanase II (in 1 % BSA) was added to each DBS. Samples were incubated at 37°C water bath overnight. The next day, the samples were centrifuged for 15 min at 2500 g. The filter plate was discarded and receiver plates stored at −20°C until injection of samples into the LC-MS/MS.
LC-MS/MS
The apparatus consisted of a 1290 Infinity LC system with a 6460 triple quad mass spectrometer (Agilent Technologies, Palo Alto, CA). Disaccharides were separated on a Hypercarb column (2.0 mm i.d. 50 mm length; 5 μm particles; Thermo Scientific, USA), thermostated at 60°C. The method was modified from that developed by Oguma et al (2007) . The mobile phase was a gradient elution of 5 mM ammonium acetate, pH 11.0 (solution A) to 5 mM ammonium acetate in 90 % acetonitrile (solution B). The flow rate was 0.7 mL/min, and the gradient was as follows: 0 min 100 % solution A, 1 min 70 % solution A, 2 min 70 % solution A, 2.20 min 0 % solution A, 2.60 min 0 % solution A, 2.61 min 100 % solution A, 5 min 100 % solution A. The mass spectrometer was operated with electrospray ionization in the negative ion mode (Agilent Jet Stream technology) with drying gas temperature 350°C, drying gas flow 11 L/min, nebulizer pressure 58 psi, sheath gas temperature 400°C, sheath gas flow 11 L/min, capillary voltage 4000 V, nozzle voltage 2000 V. Specific precursor and product ions, m/z, were used to quantify each disaccharide respectively (IS, 354.3, 193 Ratio di-sulfated KS in total KS was calculated as disulfated KS divided by (mono-sulfated KS + di-sulfated KS) × 100 %. The lower limit of quantitation (LLOQ) was defined as the lowest level of the signal with an accuracy of better than 20 % and the lower limit of detection (LOD) as a signal to noise ratio of <10 according to the Food and Drug Administration (FDA 2001) .
Statistical analysis
Sensitivity, specificity, false positive, false negative, and median absolute deviation (MAD) were performed using R software (R Core Team 2014). As most of the disaccharides were below the LLOQ (59 % for ΔDiHS-0S, 94 % for ΔDiHS-NS, 98 % for mono-sulfated KS, and 99.8 % for di-sulfated KS) in the control samples, raw calculated values used for statistical analysis GAG levels in the blood can be elevated for reasons other than MPS, resulting in a non-normal distribution and consequently the standard methodology using mean ± standard deviation to define cutoff values is not appropriate for this study. The median absolute deviation (MAD) is a robust method of central tendency, which is not sensitive to outliers (Leys et al 2013) . Cutoffs were defined as median + 7× MAD of newborn control samples. False positive samples were defined as controls that were above the cutoff values, and false negatives were defined as MPS newborn samples that were below the cutoffs. Coefficient of variation (CV) was determined at three different concentrations for the HS-0S standard (std8: 1000 ng/mL, std5: 125 ng/mL and std3: 31.25 ng/mL). Three separate preparations of each dilution were measured five times, and CV calculated as the standard deviation divided by mean × 100. It is estimated that each 3.3 mm dried blood spot disc corresponds to 3.6 μL of blood (Blanchard et al 2008) , and that concentrations of all the GAGs analyzed in this study were expressed as ng/mL of blood.
Results
Coefficient of variation (CV), lower limit of quantitation (LLOQ), and lower limit of detection (LOD) Imprecision was calculated by replicate analysis of three different concentrations (std 8, std 5, and std 3, respectively) of HS-0S, HS-NS, and DS standard (Sup. 1). LLOQs and LOD were defined for HS-0S, HS-NS, and DS (Sup. 1).
Median absolute deviation (MAD)
In order to calculate median and MAD for levels of these disaccharides in control samples, it was necessary to use calculated concentrations of these samples even though the accuracy of measurement will be low. MAD values for the control newborn samples were 10 ng/mL for HS-0S, 2 ng/mL for HS-NS, 10 ng/mL for DS, 47 ng/mL for mono-sulfated KS, 10 ng/mL for di-sulfated KS, and 2 % for ratio di-sulfated KS in total KS. To assure no false negatives, cutoffs were determined as values higher than median + 7× MAD (all patients were above cutoff for all GAGs; 7 × MAD is equivalent to more than 4 standard deviations for normally distributed data (Table 1) .
Cutoffs were >90 ng/mL for HS-0S, and >23 ng/mL for HS-NS, >88 ng/mL for DS, >445 ng/mL for mono-sulfated KS, > 89 ng/mL for di-sulfated KS, and >32 % for di-sulfated KS in total KS. Values for MPS newborn samples ranged from 145 to 463 ng/mL for HS-0S, 30 to 76 ng/mL for HS-NS, 54 to 257 ng/mL for mono-sulfated-KS, 12 to 87 ng/mL for disulfated KS, and 16 to 58 % for ratio di-sulfated KS in total KS. DS values for newborn samples with MPS I and II were between 91 and 453 ng/mL. All nine MPS I and II newborn patients had a significant elevation of DS while none of the five MPS III patients showed elevation of DS, consistent with the catabolic pathway of DS.
Sensitivity and specificity
Sensitivity was 100 % for HS-0S, HS-NS, and DS (0 % false negative rate). MPS I, II, and III do not affect KS levels, so the significance of cutoffs for KS cannot be determined. Specificity was 97 % for HS-0S, 94 % for HS-NS, 98 % for DS. Thus, the positive predictive value (PPV) for HS-0S was 16 %, 7 % for HS-NS, and 18 % for DS. The negative predictive value (NPV) was 97 % for HS-0S, 94 % for HS-NS, and 98 % for DS (Sup. 2).
HS-0S (p = 2.25576E-07), HS-NS (p = 4.15E-07), DS (p = 0.002), and ratio di-KS in total KS (p = 0.0001) were significantly higher in DBS from this cohort of MPS patients, compared to control DBS.
Of the control samples 2.5 % were above the cutoffs (median + 7× MAD) for HS-0S (Fig. 1 ), 6.2 % for HS-NS (Fig. 2) , 1.5 % for DS ( Fig. 3) , 0.3 % mono-sulfated KS, 1.6 % for di-sulfated KS, and 2.3 % for ratio di-sulfated KS in total KS. However, after combination of elevated levels for HS-0S, HS-NS, and DS, the false positive rates decreased to 0.03 % for MPS I and II and 0.9 % with combination of HS-0S and HS-NS for MPS III (Table 2 ). There were no false negative samples in the patient population.
Discussion
A major advantage of developing a measurement of GAGs as a newborn screen for MPS is that levels of one or more GAGs should be elevated in any MPS, making a single initial screen more sensitive and cost-effective for these rare disorders. A potential limitation is that GAGs can be elevated due to other conditions unrelated to MPS giving false positives [e.g.: Mucolipidosis (Tomatsu et al 2005) ; diabetes (Komosinska-Vassev et al 2005); arthritis (Mankin et al 1971) ; cancer (Hennessey et al 1981) ], as seen in the general NBS samples in this study. However, MPS I and II cause an elevation in three GAGs and MPS III causes an elevation in two GAGs, reducing the number of false positives. For this study we were able to obtain newborn DBS from 14 MPS I, II, or III patients to compare GAG levels in these samples with the ones observed in 2862 DBS from a random control sample using a cutoff of median + 7× MAD of the control sample. We were able to distinguish all of the patient samples from 99.1 % of the controls (26 out of 2862 samples) by measuring levels of HS-0S in combination with HS-NS and could distinguish the MPS I and II patients from 99.97 % (one out of 2862 samples) when levels of DS, HS-NS, and HS-0S were combined.
Considering that the combined incidence of MPS is approximately 1:20,000, it is unlikely that positive samples in the control sample set are due to MPS. The control samples were all de-identified so we were not able to determine the cause of elevated GAGs in these samples. None of the newborn MPS samples had levels of mono-sulfated KS or di-sulfated KS above the cutoffs, but eight patient samples (57 %) showed elevated levels of ratio di-sulfated KS in total KS. The ratio of di-sulfated KS in total KS was significantly higher in MPS newborn patients compared to general newborns (p = 0.0001) ( Table 1) . We have previously shown a secondary elevation of total KS and increase in ratio of di-sulfated KS in blood from older patients with other MPS types, where 40 % for MPS II patients and 54 % of MPS IVA had significantly higher levels of ratio di-sulfated KS in total KS (Shimada et al 2015; Tomatsu et al 2005 Tomatsu et al , 2014 . We did not see a secondary elevation of KS in the MPS II newborn samples, possibly due to low accumulation during early stages of bone development. KS levels are age-dependent with expected accumulation during growth and development of the skeleton. MPS IV samples would be expected to show elevated KS due to impaired GALNS metabolism, but MPS IVA newborn samples were not available to test this hypothesis. The standard deviation for the control samples is abnormally high due to a pronounced skew of the data toward higher levels, most likely due to elevated GAG levels in some newborns due to other unidentified conditions. For a population with a normal distribution, the number of false positives at mean + 2SD would be 5 %, and mean and median values would be the same. Using the MAD, we were able to limit the effects of the high outliers.
To ensure that the screen includes the majority of the patients, we based cutoffs on values from known patient samples. Availability of newborn patient samples is limited, preventing detailed statistical analysis of patient data. For MPS I and II, by measuring three GAGs (HS-0S, HS-NS, and DS) we were able to distinguish all nine patients from all but one of the 2862 controls. We did not determine whether this Bcontrol^had MPS I or II and for the purposes of this study we considered this to be a false positive. This false positive rate of 0.03 % is much lower than those for the single newborn screens for the LSDs of Pompe, Fabry, Gaucher, and MPS I that give false positive rates of 0.17, 0.4, 023, and 0.8 % respectively (Hopkins et al 2015) .
When MPS I, II, and III were included the false positive rate increased to 0.9 %. Chace and Hannon (2010) and Turgeon et al (2010) suggest that a first-tier newborn screen could be performed with less selective methodologies if they give few false negatives and limited false positives that could then be followed by a more selective second-tier screen (Fig. 4) (Chace and Hannon 2010; Turgeon et al 2010) . A better understanding of the cause of high levels of GAGs in the Bcontrol^population might help eliminate some false positives, but a first screen that eliminates 99 % of the unaffected samples would be particularly valuable in reducing the costs of more expensive enzyme or genetic tests to define the specific metabolic defect.
We have previously shown that blood from patients with other forms of MPS (IV, VI, and VII) contain elevated levels of other GAGs, but we do not have access to newborn DBS from such patients at this time and cannot directly determine GAG levels expected in newborn DBS from all MPS types (Tomatsu et al 2005 (Tomatsu et al , 2014 Rowan et al 2013; Shimada et al 2014b Shimada et al , 2015 . Nevertheless, based on data from older patients, this newborn screen is likely to capture patients with a severe form of any MPS.
Prenatal lysosomal GAG storage has been demonstrated in MPS patients and animal models. Initial clinical signs and symptoms in newborn patients with MPSs include sacral dimple, gibbus, and abnormal shape of vertebrae in X-ray images (Ohashi et al 2009) . In human, fetuses aged 18-30 weeks gestation (MPS I, II, III, and IVA) have storage vacuoles in major organs (Martin and Ceuterick 1983; Beck et al 1992) . Newborn mice with MPS I, II, IVA, or VII, have storage vacuoles as well (Tomatsu et al 2003; Vogler et al 1990) . Skeletal abnormalities represent the earliest clinical observations in MPS VII mice. Histological analysis of the growth plate, articular cartilage and cortical bone showed early pathology and progressive bone lesion . It is noteworthy that all 14 MPS newborns have an elevation of GAGs consistent with the previous findings, (Shimada et al 2014a; Tomatsu et al 2010 Tomatsu et al , 2013 de Ruijter et al 2012) demonstrating that accumulation of GAGs has already started before birth and that therapy should start at a newborn stage to prevent irreversible damage especially in bone and brain.
A limitation of this study is the low number of DBS from newborn MPS patients. Very few samples are available >Cutoff HS-0S and HS-NS 26 14 >Cutoff HS-0S and DS 6 9 a >Cutoff HS-NS and DS 8 9 a >Cutoff HS-0S, HS-NS and DS 1 9 a 14 MPS patients (I-7; II-2; III-5) a MPS III patients not included because MPS is not usually identified at birth and consequently DBS are not usually available. Thus while we were able to establish stringent cut-off values to distinguish all patient samples in this study from controls, we are not able to predict false negative rates for larger screening purposes. Another limitation is that the running time of the current LC-MS/MS (4 to 5 min per sample) is still a challenge for application to mass screening, compared to high-throughput MS/MS (10 to 12 s per sample) (Shimada et al. 2014a) . Although the main drawback of HT-MS/MS is that disaccharides with identical molecular weights cannot be distinguished, this may not be crucial for a method that is proposed as a first-tier screen to identify a high-risk group that may have an MPS. Further feasibility studies are required to compare LC-MS/MS and HT-MS/MS. In conclusion, the combination of elevated HS-0S, HS-NS, and DS seems to be a good biomarker for newborn screening of MPS I and II and HS-0S and HS-NS for MPS III. Elevated levels of GAGs will be valuable as a first-tier screen to identify a high-risk group that may have an MPS, and can be confirmed in a second-tier screen using a specific enzyme or genetic assays.
